SPONSOR
LucasBio
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
LucasBio is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including BKV Infection, EBV Infection, CMV Infection.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — LucasBio
How many clinical trials has LucasBio sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by LucasBio, of which 2 are actively recruiting participants. These trials cover conditions including BKV Infection, EBV Infection, CMV Infection. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does LucasBio research focus on?
LucasBio clinical trials span BKV Infection, EBV Infection, CMV Infection. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a LucasBio clinical trial?
To participate in a LucasBio trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all LucasBio trials with current recruitment status updated daily.
Clinical Trials by LucasBio
NCT07670468 Phase 1, Phase 2
Recruiting
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
BKV Infection
NCT07685457
Recruiting
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
BKV Infection
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology